Liège, Belgium 5 July 2016 – Mithra Pharmaceuticals announces today that it obtained a new Marketing Authorisation for the commercialization of its product Tibelia® (bioequivalent of Livial® developed by Mithra) in Spain.
Liège, Belgium 5 July 2016 – Mithra Pharmaceuticals announces today that it obtained a new Marketing Authorisation for the commercialization of its product Tibelia® (bioequivalent of Livial® developed by Mithra) in Spain.
Mithra (Euronext: MITRA) is a Belgian biotech company dedicated to transforming women’s health by offering new choices through innovation, with a particular focus on contraception and menopause.
Mithra (Headquarter)
Rue Saint-Georges 5
4000 Liège
Belgium
+32 (0)4 349 28 22
info@mithra.com
Mithra CDMO
Rue de l’Expansion 57
4400 Flémalle
Belgium
+32 (0)4 353 37 00
info@mithracdmo.com